Analysts Have Conflicting Sentiments on These Healthcare Companies: ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) and Dexcom (NASDAQ: DXCM)

By Carrie Williams

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals Inc (ACADResearch Report) and Dexcom (DXCMResearch Report).

ACADIA Pharmaceuticals Inc (ACAD)

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on ACADIA Pharmaceuticals Inc yesterday and set a price target of $31. The company’s shares closed yesterday at $23.66.

According to TipRanks.com, Kasimov is a 1-star analyst with an average return of 0.0% and a 39.9% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and Global Blood Therapeutics.

ACADIA Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $39.67, which is a 67.7% upside from current levels. In a report issued on April 25, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $30 price target.

See today’s analyst top recommended stocks >>

Dexcom (DXCM)

In a report released yesterday, Sean Lavin from BTIG maintained a Hold rating on Dexcom. The company’s shares closed yesterday at $118.62.

Lavin said:

“Dexcom posted another sizable sales beat, besting consensus expectation by almost $35M, and raised 2019 revenue guidance by $75M. The familiar topics of pricing and competition ruled much of the discussion, but there was little new on either front, in our view. Some revenue is expected to go toward higher operating expenses as the company invests in new markets, the Verily product, and G6 line extensions. We remain concerned that pricing pressures could arise—perhaps suddenly—but also may not occur for years. We frankly haven’t figured out what work to do to predict when or if insurers may push on price due to competition pricing lower. We remain Neutral as we feel we have no way to eliminate or estimate this risk but do believe DXCM shares will move higher should pricing fears not play out. CGM is good medicine and should be used by all MDI diabetics, in our view.”

According to TipRanks.com, Lavin is a 4-star analyst with an average return of 6.1% and a 54.8% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.

Dexcom has an analyst consensus of Moderate Buy, with a price target consensus of $163.13, implying a 37.5% upside from current levels. In a report released today, Northland Securities also maintained a Hold rating on the stock with a $125 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.